Emmes has announced the acquisition of Essex Management. Essex offers bioinformatics and health information technology consulting services to government, private sector, and academic organizations. This is the sixth acquisition Emmes has made in just over two years.
Like Emmes, Essex shares a successful track record with the National Cancer Institute (NCI). Emmes has provided a range of statistical and data analysis support to NCI since 1978, and Essex has supported NCI since the company's founding in 2009. Two of Essex's NCI contracts support the Clinical Trials Reporting Program, a database of all cancer clinical trials, and the Clinical Reporting and Research Informatics Initiative. Essex will add more than 100 employees to Emmes' 1,400.
Emmes Acquires Essex Management. (2023, March 21). Emmes.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.